Cargando…

Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone

BACKGROUND: Single-tablet antiretroviral therapy is currently the first-line choice for the treatment of HIV infection. Some therapeutic regimens contain the CYP3A4 inhibitor cobicistat, which can interact with drugs undergoing hepatic first-pass metabolism, leading to unintended adverse effects. CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pineda-Reyes, Roberto, Klochko, Alena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914985/ https://www.ncbi.nlm.nih.gov/pubmed/31885960 http://dx.doi.org/10.1155/2019/8243868

Ejemplares similares

Cobicistat: A case of mislabelled drug‐drug interaction risk?
por: Burger, David M., et al.
Publicado: (2020)

Rifabutin-Cobicistat Drug Interaction Resulting in Severe Bilateral Panuveitis
por: Toomey, Christopher B., et al.
Publicado: (2020)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study
por: Zhang, Yamei, et al.
Publicado: (2020)

Lost in the Mist: Acute Adrenal Crisis Following Intranasal Fluticasone Propionate Overuse
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2010)

The impact of intranasal fluticasone on patients with obstructive sleep apnea: a prospective study
por: Tam, Yuan-Yun, et al.
Publicado: (2019)

Fluticasone furoate/fluticasone propionate – different drugs with different properties
por: Biggadike, Keith
Publicado: (2011)

Preventing Cushing: Iatrogenic Cushing Syndrome due to Ritonavir-Fluticasone Interaction
por: Tiruneh, Fasil, et al.
Publicado: (2017)

Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database
por: Lehrer, Steven, et al.
Publicado: (2018)

SAT331 A Case Of Iatrogenic Cushing’s Syndrome Due To The Concomitant Use Of Cobicistat With An Inhaled Glucocorticoid Followed By Adrenal Insufficiency Upon Discontinuation Of Cobicistat
por: Noor, Laila, et al.
Publicado: (2023)

Comparative study of the efficacy and safety of intranasal azelastine hydrochloride and fluticasone furoate in the treatment of allergic rhinitis
por: Chennakeshavaraju, Nandish, et al.
Publicado: (2020)

Efficacy of intranasal fluticasone propionate and budesonide in management of allergic rhinitis—a prospective comparative study
por: Shankari, P. Kiruba, et al.
Publicado: (2021)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley, Rustin D, et al.
Publicado: (2016)

HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
por: Kang-Birken, S. Lena, et al.
Publicado: (2019)

Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency Due to an Interaction Between Fluticasone and Ritonavir
por: Gutiérrez, Lorena Suárez
Publicado: (2021)

Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents
por: Davis, Kourtney J., et al.
Publicado: (2016)

Causality Assessment of Olfactory and Gustatory Dysfunction Associated with Intranasal Fluticasone Propionate: Application of the Bradford Hill Criteria
por: Muganurmath, Chandrashekhar S., et al.
Publicado: (2018)

Effects of the common cold and intranasal fluticasone propionate treatment on mucosal host defense assessed by human saliva()()()
por: Lenander-Lumikari, Marianne, et al.
Publicado: (1999)

Erratum: “Comparative study of the efficacy and safety of intranasal azelastine hydrochloride and fluticasone furoate in the treatment of allergic rhinitis”
Publicado: (2021)

Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy
por: Shim, Tae Sun
Publicado: (2014)

Co-infection with Drug-Susceptible and Reactivated Latent Multidrug-Resistant Mycobacterium tuberculosis
por: Pérez-Lago, Laura, et al.
Publicado: (2015)

Intranasal fluticasone propionate does not prevent acute otitis media during viral upper respiratory infection in children()()
por: Ruohola, Aino, et al.
Publicado: (2000)

Comparison of sensory attributes and immediate efficacy of intranasal ciclesonide and fluticasone propionate in allergic rhinitis: A randomized controlled trial
por: Varshney, Jitendra, et al.
Publicado: (2012)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Updates on the risk factors for latent tuberculosis reactivation and their managements
por: Ai, Jing-Wen, et al.
Publicado: (2016)

Reactivation of Multifocal Choroiditis Associated with Treatment in Latent Tuberculosis
por: Bartimote, Christopher, et al.
Publicado: (2022)

Diagnosis and Treatment of Latent Tuberculosis Infection
por: Lee, Seung Heon
Publicado: (2015)

Latent Tuberculosis Infection - Diagnosis and Treatment
por: Ilievska-Poposka, Biljana, et al.
Publicado: (2018)

The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers
por: Qi, Wenyuan, et al.
Publicado: (2023)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

149 Once Daily Intranasal Fluticasone Furoate Decreases Daytime Sleepiness and Improves Cognitive Performance in Symptomatic Seasonal Allergic Rhinitis
por: Diaz, Alejandro
Publicado: (2012)

SAT340 Matters Of The HAART - Ritonavir Induced CYP3A4 Inhibition of Intranasal Fluticasone Leading To Cushing’s Syndrome
por: Ramachandran, Aishwarya, et al.
Publicado: (2023)

Iatrogenic Cushing’s Syndrome: The Result of Cobicistat and Glucocorticoid Interaction in an HIV Patient After Bariatric Surgery
por: Benido Silva, Vânia, et al.
Publicado: (2023)

Latent tuberculosis reactivation in the setting of SARS-Cov-2 infection: The analysis of the radiologic features that help the diagnosis
por: Iovino, Maria, et al.
Publicado: (2022)

Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro
por: Larson, Erica C., et al.
Publicado: (2017)

Diagnosis for Latent Tuberculosis Infection: New Alternatives
por: Carranza, Claudia, et al.
Publicado: (2020)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Data on the stability of darunavir/cobicistat suspension after tablet manipulation
por: Zanon, D., et al.
Publicado: (2020)

Multiple drugs: Latent tuberculosis (TB) reactivation, lack of efficacy and off-label use: case report
Publicado: (2021)

SIV and Mycobacterium tuberculosis synergy within the granuloma accelerates the reactivation pattern of latent tuberculosis
por: Diedrich, Collin R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cbcf8m8ohrov9s7q37d5cd6cso